Comparison of in vitro antileukemic activity of obatoclax and ABT-737Report as inadecuate




Comparison of in vitro antileukemic activity of obatoclax and ABT-737 - Download this document for free, or read online. Document in PDF available to download.

Tumor Biology

, Volume 37, Issue 8, pp 10839–10849

First Online: 15 February 2016Received: 12 November 2015Accepted: 29 January 2016

Abstract

Obatoclax and ABT-737 belong to a new class of anticancer agents known as BH3-mimetics. These agents antagonize the anti-apoptotic members of Bcl-2 family. The Bcl-2 proteins modulate sensitivity of many types of cancer cells to chemotherapy. Therefore, the objective of the present study was to examine and compare the antileukemic activity of obatoclax and ABT-737 applied alone, and in combination with anticancer agent, mafosfamide and daunorubicin. The in vitro cytotoxic effects of the tested agents on human leukemia cells were determined using the spectrophotometric MTT test, Coulter electrical impedance method, flow cytometry annexin V–fluorescein-propidium iodide assay, and light microscopy technique. The combination index analysis was used to quantify the extent of agent interactions. BH3 mimetics significantly decreased the leukemia cell viability and synergistically enhanced the cytotoxic effects induced by mafosfamide and daunorubicin. Obatoclax affected the cell viability to a greater degree than did ABT-737. In addition, various patterns of temporary changes in the cell volume and count, and in the frequency of leukemia cells undergoing apoptosis, were found 24 and 48 h after the tested agent application. ABT-737 combined with anticancer agents induced apoptosis more effectively than obatoclax when given in the same combination regimen. The results of the present study point to the different antileukemic activities of obatoclax and ABT-737, when applied alone, and in combination with anticancer agents. A better understanding of the exact mechanisms of BH3 mimetic action is of key importance for their optional use in cancer therapy.

KeywordsBH3 mimetics Obatoclax ABT-737 Anticancer agents Antileukemic activity  Download fulltext PDF



Author: Małgorzata Opydo-Chanek - Lidia Mazur

Source: https://link.springer.com/article/10.1007/s13277-016-4943-z







Related documents